ABLYNX ANNOUNCES WARRANT EXERCISE

ABLYNX ANNOUNCES WARRANT EXERCISE

REGULATED INFORMATION

GHENT, Belgium, Nov. 26, 2013 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels:
ABLX] today announced, in conformity with Title II of the Law of 2 May 2007
and the Royal Decree of 14 February 2008, that an additional 165,000 common
shares have been issued by the Company in exchange for 330,000 Euro as the
result of the exercise of warrants by some employees and consultants of the
Company.

As a result of this transaction, Ablynx now has 48,992,646 shares outstanding.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development
of Nanobodies^®, a novel class of therapeutic proteins based on  single-domain 
antibody  fragments,  for  a  range  of  serious  human  diseases,   including 
inflammation, haematology, oncology and pulmonary disease. Today, the  Company 
has approximately  30  programmes in  the  pipeline and  seven  Nanobodies  at 
clinical development  stage. Ablynx  has ongoing  research collaborations  and 
significant partnerships with major pharmaceutical companies including AbbVie,
Boehringer Ingelheim, Merck &  Co, Merck Serono and  Novartis. The Company  is 
headquartered  in  Ghent,   Belgium.  More   information  can   be  found   on 
www.ablynx.com.

pdf          version          of          the          press          release: 
http://hugin.info/137912/R/1745953/587653.pdf

For more information, please contact

Ablynx:

Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
 +32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com
Follow us on Twitter @AblynxABLX

Ablynx media relations Consilium Strategic Communications:

Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t: +44 207 920 2345
e: ablynx@consilium-comms.com